[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6212 followers Created: 2025-07-26 06:11:06 UTC Alembic Pharma Secures USFDA Approval for Carbamazepine Tablets 💊 | Market Potential: $71M | MCap XXXXXXXX Cr - USFDA grants final approval for Carbamazepine Extended-Release Tablets (100mg, 200mg, 400mg). - Therapeutically equivalent to Novartis' Tegretol-XR. - Used for anticonvulsant therapy and trigeminal neuralgia pain. - Estimated market size: $71M (12 months ending March 2025, per IQVIA). - Cumulative USFDA approvals: XXX (202 final + XX tentative). - Vertically integrated R&D pharma company with strong branded generics presence in India. - Operates with 5,500+ field force personnel and USFDA-approved manufacturing facilities. Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.  XXX engagements  **Related Topics** [mcap](/topic/mcap) [$71m](/topic/$71m) [investment](/topic/investment) [novartis](/topic/novartis) [$novnsw](/topic/$novnsw) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/_Investor_Feed_/status/1948989433195139199)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Investor Feed @Investor_Feed on x 6212 followers
Created: 2025-07-26 06:11:06 UTC
Alembic Pharma Secures USFDA Approval for Carbamazepine Tablets 💊 | Market Potential: $71M | MCap XXXXXXXX Cr
Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.
XXX engagements
Related Topics mcap $71m investment novartis $novnsw stocks healthcare
/post/tweet::1948989433195139199